Cost-utility analysis of a national project to reduce hypertension in Israel
<p>Abstract</p> <p>Background</p> <p>This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program.</p> <p>Methods</p> <p>Interventions are based on experience from our two programs:...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2007-11-01
|
Series: | Cost Effectiveness and Resource Allocation |
Online Access: | http://www.resource-allocation.com/content/5/1/16 |
id |
doaj-fb23f1be3d104a30bfbcaf39704ed271 |
---|---|
record_format |
Article |
spelling |
doaj-fb23f1be3d104a30bfbcaf39704ed2712020-11-25T02:28:57ZengBMCCost Effectiveness and Resource Allocation1478-75472007-11-01511610.1186/1478-7547-5-16Cost-utility analysis of a national project to reduce hypertension in IsraelDicker DrorViskoper ReuvenGinsberg GaryYosefy ChaimGavish Dov<p>Abstract</p> <p>Background</p> <p>This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program.</p> <p>Methods</p> <p>Interventions are based on experience from our two programs: 10-year period of Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on economic data, training staff levels, course frequency and unit costs.</p> <p>Results</p> <p>Over the next 20 years, the program should decrease the risk in one-half of the treated hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality.</p> <p>Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity decreases, exceed costs by $185.0 million.</p> <p>Conclusion</p> <p>The project which saves both lives and resources should be extended nation-wide to reach as wide a population as possible.</p> http://www.resource-allocation.com/content/5/1/16 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dicker Dror Viskoper Reuven Ginsberg Gary Yosefy Chaim Gavish Dov |
spellingShingle |
Dicker Dror Viskoper Reuven Ginsberg Gary Yosefy Chaim Gavish Dov Cost-utility analysis of a national project to reduce hypertension in Israel Cost Effectiveness and Resource Allocation |
author_facet |
Dicker Dror Viskoper Reuven Ginsberg Gary Yosefy Chaim Gavish Dov |
author_sort |
Dicker Dror |
title |
Cost-utility analysis of a national project to reduce hypertension in Israel |
title_short |
Cost-utility analysis of a national project to reduce hypertension in Israel |
title_full |
Cost-utility analysis of a national project to reduce hypertension in Israel |
title_fullStr |
Cost-utility analysis of a national project to reduce hypertension in Israel |
title_full_unstemmed |
Cost-utility analysis of a national project to reduce hypertension in Israel |
title_sort |
cost-utility analysis of a national project to reduce hypertension in israel |
publisher |
BMC |
series |
Cost Effectiveness and Resource Allocation |
issn |
1478-7547 |
publishDate |
2007-11-01 |
description |
<p>Abstract</p> <p>Background</p> <p>This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program.</p> <p>Methods</p> <p>Interventions are based on experience from our two programs: 10-year period of Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on economic data, training staff levels, course frequency and unit costs.</p> <p>Results</p> <p>Over the next 20 years, the program should decrease the risk in one-half of the treated hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality.</p> <p>Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity decreases, exceed costs by $185.0 million.</p> <p>Conclusion</p> <p>The project which saves both lives and resources should be extended nation-wide to reach as wide a population as possible.</p> |
url |
http://www.resource-allocation.com/content/5/1/16 |
work_keys_str_mv |
AT dickerdror costutilityanalysisofanationalprojecttoreducehypertensioninisrael AT viskoperreuven costutilityanalysisofanationalprojecttoreducehypertensioninisrael AT ginsberggary costutilityanalysisofanationalprojecttoreducehypertensioninisrael AT yosefychaim costutilityanalysisofanationalprojecttoreducehypertensioninisrael AT gavishdov costutilityanalysisofanationalprojecttoreducehypertensioninisrael |
_version_ |
1724835406283800576 |